|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2007
Decision Resources, Inc., Jan 2008, Pages: 30
Introduction
The fourth quarter of 2007 was fairly quiet in the pricing and reimbursement arena. In the United States, the presidential election, legislation in California, and a new initiative from health plans focused attention on the uninsured and universal coverage. A public consultation on the future of pharmaceuticals highlighted the challenges confronting drug manufacturers in Europe, while the Japanese government seemingly changed course on overhauling its pharmaceutical pricing and reimbursement system.
Get the Answers You Need to Shape Your Strategy
- Pending U.S. legislation would allow the Department of Health and Human Services to create a national Medicare formulary. How would HHS use this formulary in its price negotiations with pharmaceutical manufacturers?
- U.S. employers and health plans are recognizing the fi nancial and health benefi ts of promoting greater use of generic drugs and improved adherence to chronic disease therapy. What strategies are they pursuing in their efforts to improve patient adherence with chronic disease therapy and encourage the use of generics?
- Pressure to tackle the growth in the ranks of uninsured U.S. residents is mounting. Which states have enacted their own universal coverage legislation? How will the presidential election affect this issue at the national level?
Scope
- Overview: major events in the fourth quarter of 2007 in the pricing, reimbursement, and prescribing environment in the major pharmaceutical markets under study.
- United States: leading stories in 2007, including SCHIP, decline in drug imports, copayment reductions and waivers for generics and chronic disease therapies, and many others.
- European Union: responses to public consultation on the future of pharmaceuticals in Europe.
- France: pressures on pharmaceutical industry, potential reforms for chronic disease treatments.
- Germany: new reference pricing groups, health economic evaluation, growth in rebate contracts.
- Italy: market trends in 2007.
- Spain: amendments to the reference pricing system.
- United Kingdom: proposed amendments to NICE’s methods for technology appraisals, OFT report on direct-to-pharmacy distribution, abolition of prescription charges in Scotland.
- Japan: delay in overhaul of pricing and reimbursement system, efforts to increase use of generics.
- Outlook and implications for the pharmaceutical industry: the outlook for pharma in the United States, Europe, and Japan.
Also available
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2006
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2007
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Second Quarter of 2007
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2007
Pharmaceutical Pricing and Reimbursement in the United States, 2008
Customers who bought this item also bought
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2007
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2008
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Second Quarter of 2007
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2007
Pharmaceutical Pricing and Reimbursement in the United States, 2008
Pharmaceutical Pricing and Reimbursement in France, 2008
Strategic Overview of Pharmaceutical Pricing and Reimbursement in the Major Markets
Pharmaceutical Pricing and Reimbursement in the United Kingdom, 2008
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2006
Pricing and Reimbursement in the United Arab Emirates
Pricing and Reimbursement Issues for Immune Disease Therapies
Pharmaceutical Market Access, Pricing, and Reimbursement News in the Third Quarter of 2009
|
|
|
|
